OverviewSuggest Edit

Sana Biotechnology is a company specializing in cell and gene therapy. It focuses on creating and delivering engineered cells as medicines for patients. The company deploys a platform that can repair and control genes in cells or replace any cell in the body.
TypePublic
Founded2018
HQSeattle, WA, US
Websitesana.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Sept 2020)240(+549%)
Job Openings51
Share Price (Aug 2021)$17.6(+7%)
Cybersecurity ratingAMore

Key People/Management at Sana Biotechnology

Steve Harr

Steve Harr

President and Chief Executive Officer, Director
Robin Andrulevich

Robin Andrulevich

Chief People Officer
Nate Hardy

Nate Hardy

Chief Financial Officer
Christian Hordo

Christian Hordo

Chief Business Officer
Jim MacDonald

Jim MacDonald

General Counsel
Sunil Agarwal

Sunil Agarwal

Head of Development and Chief Medical Officer
Show more

Sana Biotechnology Office Locations

Sana Biotechnology has offices in Seattle, Cambridge and South San Francisco
Seattle, WA, US (HQ)
188 E Blaine St #400
Cambridge, MA, US
300 Tech Square, 300 Technology Square #700
South San Francisco, CA, US
1 Tower Pl #500
Show all (3)

Sana Biotechnology Financials and Metrics

Sana Biotechnology Revenue

USD

Net income (Q1, 2021)

(180.6m)

EBIT (Q1, 2021)

(180.8m)

Market capitalization (3-Aug-2021)

3.3b

Closing stock price (3-Aug-2021)

17.6

Cash (31-Mar-2021)

750.7m

EV

2.7b
Sana Biotechnology's current market capitalization is $3.3 b.
Annual
USDFY, 2018FY, 2019

General and administrative expense

4.2m21.8m

R&D expense

9.0m119.4m

Operating expense total

13.2m141.2m

EBIT

(13.2m)(141.2m)
Quarterly
USDQ1, 2021

General and administrative expense

11.8m

R&D expense

168.9m

Operating expense total

180.8m

EBIT

(180.8m)
Annual
USDFY, 2018FY, 2019

Cash

30.6m80.0m

Current Assets

32.6m144.3m

PP&E

585.0k27.9m

Goodwill

140.6m
Quarterly
USDQ3, 2020Q1, 2021

Cash

149.2m750.7m

Prepaid Expenses

7.2m

Current Assets

455.6m967.5m

PP&E

39.8m51.0m
Annual
USDFY, 2018FY, 2019

Net Income

(13.2m)(130.8m)

Depreciation and Amortization

1.0k1.8m

Accounts Payable

289.0k(421.0k)

Cash From Operating Activities

(13.5m)(85.5m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(87.7m)(172.1m)(180.6m)

Depreciation and Amortization

798.0k4.2m

Accounts Payable

469.0k2.4m1.6m

Cash From Operating Activities

(51.7m)(100.4m)(49.9m)
USDFY, 2018

Financial Leverage

-2.6 x
Show all financial metrics

Sana Biotechnology Operating Metrics

Q3, 2020

Pre-Clinical Phase Products

14
Show all operating metrics

Sana Biotechnology Acquisitions / Subsidiaries

Company NameDateDeal Size
Cobalt Biomedicine, Inc.
Cytocardia, Inc.
Oscine Corp.

Sana Biotechnology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Sana Biotechnology Online and Social Media Presence

Embed Graph

Sana Biotechnology News and Updates

Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates

Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression

Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting

SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual …

Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on We…

Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021

— Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes —

Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021

– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogenresults in tumor eradication –– Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tumor eradication –
Show more

Sana Biotechnology Frequently Asked Questions

  • When was Sana Biotechnology founded?

    Sana Biotechnology was founded in 2018.

  • Who are Sana Biotechnology key executives?

    Sana Biotechnology's key executives are Steve Harr, Robin Andrulevich and Nate Hardy.

  • How many employees does Sana Biotechnology have?

    Sana Biotechnology has 240 employees.

  • Who are Sana Biotechnology competitors?

    Competitors of Sana Biotechnology include Nuclera, Definigen and Covalab.

  • Where is Sana Biotechnology headquarters?

    Sana Biotechnology headquarters is located at 188 E Blaine St #400, Seattle.

  • Where are Sana Biotechnology offices?

    Sana Biotechnology has offices in Seattle, Cambridge and South San Francisco.

  • How many offices does Sana Biotechnology have?

    Sana Biotechnology has 3 offices.